Kazia Therapeutics launches paxalisib Trial in combination with Immunotherapy in Women with Advanced Breast Cancer

January 30, 2025

DENVER, Colo., Jan 30, 2025 (247marketnews.com)- Kazia Therapeutics (NASDAQ:KZIA) announced receiving regulatory approval for a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer, which it launched.

Kazia Therapeutics Limited Logo

The ABC-Pax trial potentially represents a significant development in the treatment of triple-negative breast cancer (TNBC), one of the most aggressive and treatment-resistant types of breast cancer. The combination of paxalisib and immunotherapies like KEYTRUDA (pembrolizumab) or LYNPARZA (olaparib) is particularly promising due to the innovative approach of targeting dormant cancer cells and enhancing the immune response.

Kazia Therapeutics CEO, Dr John Friend, stated, “The novelty of the science that Professor Rao has proposed with this dual combination of paxalisib and immunotherapy could advance the treatment of women with aggressive breast cancer, and we are excited to support this unique clinical study.”

The trial’s focus on paxalisib, a drug designed to reprogram dormant cancer cells and make them more visible to the immune system, in combination with immunotherapies, aims to address two key challenges in treating TNBC: immune evasion and tumor resistance. By targeting these dormant cancer cells, the combination therapy could potentially reduce recurrence rates and improve survival outcomes, an area where current treatments for TNBC often struggle.

Sudha Rao, QIMR Berghofer Professor, added, “There is no cure for triple negative breast cancer and the life expectancy for these women is tragically short. We want to identify treatments to extend the duration and quality of life of these patients. The hope is to prolong patient survival through the new combined therapy, which targets the dormant cancer cells that drive the spread and recurrence of the disease and rejuvenates the immune system to more effectively fight the cancer.”

The preclinical data presented at the San Antonio Breast Cancer Symposium supports this theory, showing synergies between paxalisib and checkpoint inhibitors like pembrolizumab (KEYTRUDA), as well as PARP inhibitors like olaparib (LYNPARZA). These findings are encouraging, suggesting that this combination could overcome the resistance that some triple-negative breast cancers develop against standard immunotherapy.

Additionally, the incorporation of liquid biopsy technology for monitoring treatment response in real-time through blood samples is an exciting development. This non-invasive method could provide a more dynamic and personalized approach to treatment by tracking cancer behavior and immune responses as they evolve, offering crucial insights for adjusting treatment strategies.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KZIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.